Drug Trial Radar · NCT06051695
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
474
Planned (sponsor's estimate)
Start
Apr 3, 2024
Primary completion
Jun 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- A2 Biotherapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Tempus AI
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose
Conditions
- Solid Tumor, Adult
- Colorectal Cancer
- NSCLC
- Non Small Cell Lung Cancer
- NSCLC, Recurrent
- Non-Small Cell Squamous Lung Cancer
- Pancreas Cancer
- Pancreatic Neoplasm
- Colorectal Adenocarcinoma
- CRC
- Colon Cancer
- Rectal Cancer
- Cancer
- Ovarian Cancer
- Ovarian Neoplasms
- Mesothelioma
- Mesothelioma, Malignant
- Ovary Cancer
- Lung Cancer
- MESOM
Interventions
A2B694Biological
Autologous logic-gated Tmod CAR T cells
A2B543Biological
Autologous logic-gated Tmod CAR T cells
xT CDx with HLA-LOH AssayDiagnostic test
An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose levelTime frame: From the time of Informed consent until 24 months (2 years) post infusion
- Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: 21 days post infusion
- Phase 2: The Overall Response Rate (ORR) for patientsTime frame: 24 months post infusion
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Banner Health
Gilbert, Arizona
UCSD Moores Cancer Center
La Jolla, California
UCLA Medical Center
Los Angeles, California
Stanford University
Stanford, California
Mayo Clinic
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Mayo Clinic Rochester
Rochester, Minnesota
Washington University
St Louis, Missouri
NYU Langone Medical Center
New York, New York
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Fred Hutchinson Cancer Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.